SIGN UP
LOG IN
News
OSUR
5.25
0.00%
0.00
Lacklustre Performance Is Driving OraSure Technologies, Inc.'s (NASDAQ:OSUR) Low P/S
OraSure Technologies, Inc. Has a price-to-sales ratio of 1x. The company's revenue growth is expected to be lower than the rest of the Medical Equipment industry in the next three years. Ora sure Technologies' P/S ratio is below the average for the industry. It has a poor outlook for revenue growth and is not expected to grow much in the future.
Simply Wall St · 1d ago
Weekly Report: what happened at OSUR last week (0408-0412)?
Weekly Report · 3d ago
OraSure reports cybersecurity breach, says incident has been contained
Healthcare OraSure reports cybersecurity breach, says incident has been contained. Unauthorized third party gained access to the company's data. The diagnostics maker says it has contacted law enforcement and is investigating the matter. Ora sure says the incident has now been contained and is not expected to affect its operations.
Seeking Alpha · 6d ago
OraSure Technologies Hit With Cybersecurity Breach
OraSure Technologies says an unauthorized third party accessed company data late last month. The diagnostic test maker says the company believes it has contained the breach. The company says the breach hasn't had a material impact on the company. OraSure reiterated its revenue guidance for first quarter of 2024.
Dow Jones · 6d ago
ORASURE TECHNOLOGIES: DOES NOT ANTICIPATE THIS INCIDENT WILL HAVE MATERIAL IMPACT ON ITS FINANCIAL CONDITION AND RESULTS OF OPERATIONS MOVING FORWARD
Reuters · 6d ago
Weekly Report: what happened at OSUR last week (0401-0405)?
Weekly Report · 04/08 09:22
OraSure Price Target Cut to $6.50/Share From $7.00 by Evercore ISI Group
Dow Jones · 04/04 17:05
OraSure Is Maintained at In-Line by Evercore ISI Group
Dow Jones · 04/04 17:05
Evercore ISI Group Maintains In-Line on OraSure Technologies, Lowers Price Target to $6.5
Benzinga · 04/04 16:54
Top buy-rated stocks and sell-rated stocks within Health Care - Citi
Citi Research strategists have lowered the health care sector to underweight. The company has struggled with “uninspiring” growth in equipment and services. Pharmaceuticals, biotechnology and life sciences are the top sell-rated stocks within the sector. The top buy-rated stock is Arcus Biosciences.
Seeking Alpha · 04/04 15:12
ORASURE TECHNOLOGIES INC <OSUR.O>: EVERCORE ISI CUTS TARGET PRICE TO $6.5 FROM $7
Reuters · 04/04 11:38
Weekly Report: what happened at OSUR last week (0325-0329)?
Weekly Report · 04/01 09:21
Weekly Report: what happened at OSUR last week (0318-0322)?
Weekly Report · 03/25 09:22
Atrion Corporation Is Overvalued For The Direction Fundamentals Are Heading
Atrion Corporation is a healthcare company focused on fluid delivery products. The company has experienced a decline in revenue, profits, and cash flows. The stock is currently expensive compared to similar companies. Despite the potential for improvement in the future, the company is overvalued. Atrion has been downgraded to a 'sell' rating.
Seeking Alpha · 03/24 12:34
Weekly Report: what happened at OSUR last week (0311-0315)?
Weekly Report · 03/18 09:22
Orasure Tech: Annual report
Press release · 03/11 22:22
Weekly Report: what happened at OSUR last week (0304-0308)?
Weekly Report · 03/11 09:21
Weekly Report: what happened at OSUR last week (0226-0301)?
Weekly Report · 03/04 09:22
Earnings Beat: OraSure Technologies, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
OraSure Technologies, Inc. (NASDAQ:OSUR) released its latest full-year results last week. The company's shares gained 7.2% to US$7.20 after the results. Revenues were US$405m, and statutory earnings per share were 33% ahead of estimates. The analysts have downgraded their revenue estimates for the company for 2024. The consensus is for a 53% decline in revenue and a loss per share in 2024. However, the analysts have not changed their valuation of the company.
Simply Wall St · 03/01 12:24
More
Webull provides a variety of real-time OSUR stock news. You can receive the latest news about Orasure Tech through multiple platforms. This information may help you make smarter investment decisions.
About OSUR
OraSure Technologies, Inc. provides point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services. The Company's product portfolio is divided into diagnostics products and sample management solutions. Its business consists of the development, manufacture, marketing and sale of diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its diagnostic products include tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. Its business also includes molecular sample management solutions and services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.